Clinical trial register · South Korea

Clinical Trials in Suwon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC

3365

Studies in scope

all four open statuses

1831

Recruiting now

open to new participants

500

Lead sponsors

across recruiting studies

Top sites

Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396

Trials with a site in Suwon

Status

Study

Lead sponsor

Phase

Enrol

Sites in South Korea

Start

Not yet open

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

NCT07668401Obesity, Overweight

DrugZenagamtide

Novo Nordisk A/S

Phase 3

400

Seoungnam-si, Suwon, Yangsan, Daegu, Seoul

2027-01-07

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Bucheon-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon

2026-10-26

Not yet open

Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years

NCT07791186Prevention of COVID-19 Variant (Omicron JN.1)

BMI Korea

Phase 1

Seoul, Suwon

2026-10-01

Recruiting

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189Oropharyngeal Carcinoma (OPC)

DrugsCRB-701·Cetuximab·Docetaxel

Corbus Pharmaceuticals Inc.

Phase 3

260

Busan, Jeonju, Seongnam, Seongnam-si, Seoul, Suwon, Yangsan

2026-09-29

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

Busan, Daegu, Daejeon, Incheon, Seoul, Suwon

2026-08-20

Recruiting

STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure

NCT07631156Heart Failure With Reduced Ejection Fraction, Heart Failure, Ventricular Dysfunction, Left

Kyungsub Song

Phase 4

Daegu, Seongnam-si, Suwon, Yangsan, Seoul

2026-08-12

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Seoul, Suwon

2026-07-27

Recruiting

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma

NCT07699939Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsSerplulimab·Oxaliplatin

National Cancer Center, Japan

Phase 2

136

Goyang-si, Suwon, Seocho, Songpa-dong

2026-07-15

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, Suwon

2026-06-29

Not yet open

NAVO:J School-Based Group Intervention for Adolescent Mental Health

NCT07667179Resilience, Depression

Ajou University School of Medicine

Not applicable

250

Suwon

2026-06-24

Recruiting

The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)

NCT06995625Acute Ischemic Stroke AIS

S&Ebio Co. Ltd.

Phase 1

Suwon, Seoul

2026-06-22

Recruiting

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

NCT07554339Non-small Cell Lung Cancer

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Phase 3

310

Goyang-si, Suwon, Cheongju-si, Daegu, Seoul

2026-06-18

Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

460

Suwon, Jeonju, Seoul, Busan

2026-05-27

Recruiting

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 3

990

Busan, Incheon, Seongnam, Suwon, Hwasun-gun, Seoul

2026-05-22

Recruiting

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

NCT07393282High Risk Smoldering Multiple Myeloma (HR-SMM)

DrugsLinvoseltamab·Darzalex·Daratumumab

Regeneron Pharmaceuticals

Phase 3

270

Suwon, Seoul

2026-05-21

Recruiting

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

NCT07572032Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy, Heart Failure

DrugSacubitril / Valsartan

Kyungsub Song

Phase 4

Daegu, Seongnam-si, Suwon, Seoul

2026-05-20

Recruiting

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

NCT07541287IgA Nephropathy

DrugJADE101

Jade Biosciences, Inc.

Phase 2

Anyang-si, Seongnam-si, Seoul, Suwon

2026-05-19

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Daegu, Wŏnju, Bundang Gu, Suwon, Incheon, Seoul, Busan, Gwangju

2026-05-11

Recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001Obesity, Heart Failure

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

5,610

Wŏnju, Anyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Daegu, Daejeon

2026-05-11

Recruiting

A Study of PLH-2301 in Subjects With Sarcopenia

NCT07390552Sarcopenia in Elderly

Pluto Inc.

Phase 2

168

Seongnam-si, Suwon, Seoul

2026-05-08

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

Goyang-si, Seongnam-si, Suwon, Cheongju-si, Seoul

2026-05-04

Recruiting

Remibrutinib Open Label Roll-over Post-trial Access Protocol

NCT07456891Indication of the Parent Protocol

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

648

Daegu, Hwaseong-si, Suwon, Dongjak Gu, Seoul, Gwangju, Incheon

2026-04-16

Recruiting

Safety and Effectiveness of GENOSS PCB in Patients With Long Femoropopliteal Lesion

NCT07425171PTA (Percutaneous Transluminal Angioplasty), Femoropopliteal Artery Disease, Long Femoropopliteal Artery Disease

Genoss Co., Ltd.

Observational

300

Suwon

2026-04-13

Recruiting

A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea

NCT07520747Inflammatory Bowel Diseases

Janssen Korea, Ltd., Korea

Observational

8,000

Suwon

2026-04-07

Recruiting

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT07493265Narcolepsy

DrugE2086

Eisai Inc.

Phase 2

Seongnam-si, Daegu, Seoul, Suwon

2026-03-26

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Seoul, Suwon

2026-03-23

Recruiting

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Calderasib

Merck Sharp & Dohme LLC

Phase 3

400

Goyang-si, Suwon, Daegu, Seoul

2026-03-18

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Changwon-si, Goyang-si, Seongnam, Seongnam-si, Seoul, Suwon

2026-03-05

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Busan, Gwangju, Gyeonggi-do, Seoul, Suwon

2026-03-05

Active, closed

Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients

NCT07101380Mild Cognitive Impairment (MCI)

Ajou University School of Medicine

Not applicable

Seongnam-si, Suwon, Busan, Gwangju

2026-02-23

Not yet open

Consistency of ASIS Line vs. Tuffier's Line for Lumbar Level Identification

NCT07396961Spinal Anesthesia Evaluation, Lumbar Vertebrae

Kangbuk Samsung Hospital

Observational

140

Suwon, Seoul

2026-02-20

Recruiting

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

DrugsLevofolinate·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Global Development, Inc.

Phase 3

614

Cheongju-si, Incheon, Seongnam-si, Seoul, Suwon

2026-02-17

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Busan, Gangnam-gu, Goyang, Seoul, Suwon

2026-02-16

Recruiting

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

NCT07187401Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia

Regeneron Pharmaceuticals

Phase 1/2

Suwon, Seoul

2026-02-11

Recruiting

A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer

NCT07853209Prostate Cancer, mCRPC

FutureChem

Phase 3

114

Gyeonggi-do, Seoul, Suwon

2026-01-26

Recruiting

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer

DrugsKeytruda·Pembrolizumab

Eikon Therapeutics

Phase 1/2

160

Suwon

2026-01-20

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Goyang, Seongnam, Seoul, Suwon

2026-01-16

Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion

DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2/3

590

Cheongju-si, Goyang-si, Seongnam, Suwon, Seoul

2026-01-02

Recruiting

AI ECG Algorithm for Detecting LV Systolic Dysfunction

NCT07636759HF - Heart Failure

Ajou University School of Medicine

Observational

1,500

Suwon

2026-01-01

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Busan, Daegu, Goyang-si, Seongnam-si, Seoul, Suwon, Yangsan

2025-12-29

Active, closed

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

360

Daegu, Seongnam-si, Suwon, Cheongju-si, Goyang-si, Pusan, Yangsan, Jinju

2025-12-22

By invitation

The SMART Trial: Modified Single-Stapled Anastomosis in Laparoscopic or Robotic Low Anterior Resection for Rectal Cancer

NCT07376980Rectal Neoplasms, Rectal Neoplasms Malignant, Rectal Cancer, Rectal Cancer Surgery

Korea University Anam Hospital

Not applicable

450

Suwon, Daegu, Seoul

2025-12-20

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

480

Suwon, Hwasun, Incheon, Seoul

2025-12-17

Recruiting

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery

Ascendis Pharma A/S

Phase 3

186

Sejong, Seongnam, Seoul, Suwon

2025-12-12

Active, closed

Evaluation of Safety and Efficacy of a Digital Therapeutic Device to Improve Strength in Sarcopenia (Sarc-DTx)

NCT07319377Sarcopenia

Exosystems

Not applicable

130

Bucheon-si, Suwon

2025-11-28

By invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

1,370

Ansan, Seoul, Suwon

2025-11-25

Recruiting

Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease

NCT07239310Mild Cognitive Impairment, Alzheimer's Disease(AD)

Deepsonbio

Not applicable

138

Cheonan, Hwaseong-si, Incheon, Seongnam-si, Suwon, Seoul

2025-11-20

Recruiting

AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM

NCT07347691Embolic Stroke of Undetermined Source

Inha University Hospital

Observational

Ansan, Incheon, Jeju City, Seoul, Suwon

2025-11-19

By invitation

WEgovy Real World Assessment of Weight Loss in Korea

NCT07280221Obesity

DrugSemaglutide

Novo Nordisk A/S

Observational

500

Goyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon

2025-11-10

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Cheongju-si, Goyang-si, Seongnam, Suwon, Seoul

2025-11-05

Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Ribociclib·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

1,000

Busan, Daegu, Goyang-si, Seongnam-si, Suwon, Yongin-si, Seoul

2025-11-03

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

Goyang-si, Incheon, Seoul, Suwon

2025-10-31

Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751Breast Neoplasms

DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin

BioNTech SE

Phase 3

558

Cheonan, Cheongju-si, Goyang-si, Seongnam-si, Seoul, Suwon

2025-10-30

Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126Non-small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

686

Cheongju-si, Goyang-si, Jinju, Seongnam, Seoul, Suwon

2025-10-24

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Daegu, Goyang-si, Seongnam, Seoul, Suwon

2025-10-22

Recruiting

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

NCT06927648Breast Cancer

AstraZeneca

Observational

130

Busan, Daejeon, Goyang-si, Guri-si, Incheon, Seongnam-si, Seoul, Suwon

2025-10-15

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Busan, Daegu, Daejeon, Dongdaemun-gu, Seongnam-si, Seoul, Suwon

2025-10-03

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Busan, Daegu, Daejeon, Seoul, Suwon

2025-10-01

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

980

Ansan-si, Busan, Daegu, Daejeon, Gwangju, Seoul, Suwon

2025-10-01

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

Cheongju-si, Goyang-si, Seongnam, Seongnam-si, Suwon, Haeundae-gu, Dongjak-gu, Seoul

2025-09-29

Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196Immunoglobulin G4 Related Disease

DrugRilzabrutinib

Sanofi

Phase 3

124

Suwon, Seoul

2025-09-26

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Busan, Daejeon, Goyang, Seongnam, Seoul, Suwon

2025-09-08

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

Daegu, Gwangju, Namdong-gu, Seongnam, Seoul, Suwon, Ulsan

2025-09-02

Recruiting

A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia

NCT07016269Biliary Dyspepsia

Myungmoon Pharma. Co. Ltd.

Phase 4

358

Ansan, Suwon, Busan, Gyeonggi-do, Incheon, Seoul

2025-08-29

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

Cheongju-si, Namdong-gu, Seongnam-si, Seoul, Suwon

2025-08-07

Recruiting

Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

NCT07027072Mild Cognitive Impairment (MCI), Mild Dementia, Alzheimer's Disease

DrugKDS2010

NeuroBiogen Co., Ltd

Phase 2

114

Gwangju, Guri-si, Suwon, Incheon, Seoul

2025-08-06

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Goyang-si, Gwangjin-gu, Seoul, Songpa-gu, Suwon

2025-08-01

Recruiting

Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study

NCT07395752Suicidal Ideation, Self-Injurious Behavior, Suicide, Attempted

Ajou University School of Medicine

Not applicable

100

Suwon

2025-07-30

Recruiting

Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients

NCT07009171Overweight, Obesity, Obese Patients

DrugKDS2010

NeuroBiogen Co., Ltd

Phase 2

Suwon, Seoul

2025-07-29

Recruiting

A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).

NCT07005752Cholesterol Cholelithiasis

Myungmoon Pharma. Co. Ltd.

Phase 4

484

Ansan, Bucheon-si, Suwon, Busan, Daegu, Gyeonggi-do, Incheon, Seoul

2025-07-28

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

Goyang, Incheon, Seongnam-si, Seoul, Suwon, Ulsan

2025-07-24

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

Hwasun-gun, Seongnam, Suwon, Busan, Haeundae-gu, Seoul, Deagu

2025-07-23

Recruiting

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

NCT06824168Acute Myeloid Leukemia, Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 2

130

Busan, Daegu, Goyang-si, Incheon, Jeonju, Seongnam, Seoul, Suwon

2025-07-18

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux

Merck Sharp & Dohme LLC

Phase 3

477

Goyang-si, Seongnam-si, Suwon, Gangnam, Songpa-gu, Buk-Gu, Seoul

2025-07-16

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Suwon, Seongnam-si, Seoul

2025-07-15

Recruiting

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352Alzheimers Disease

Hoffmann-La Roche

Phase 3

80,000

Gwangju, Gyeonggi-do, Incheon, Namdong-gu, Seongnam-si, Seoul, Suwon

2025-07-02

Recruiting

A Study of AMC6156 in People With Sarcopenia

NCT07072195Sarcopenia in Elderly, Sarcopenia

Animuscure Inc.

Phase 2

Seongnam-si, Suwon, Seoul

2025-07-01

Recruiting

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

NCT07033026Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia

NGM Biopharmaceuticals, Inc

Phase 2

136

Goyang, Incheon, Seoul, Suwon

2025-06-25

Active, closed

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

NCT06736990Idiopathic Pulmonary Fibrosis

Calluna Pharma AS

Phase 2

150

Suwon, Gyeonggi-do, Seoul

2025-06-20

Recruiting

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT06972446Rheumatoid Arthritis

DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab

AbbVie

Phase 2

180

Cheonan-si, Suwon, Seoul

2025-06-20

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Busan, Daegu, Daejeon, Seongnam-si, Suwon, Gwangju, Seoul

2025-06-17

Recruiting

Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy

NCT06984952Enhanced Recovery After Surgery, Gastrectomy for Gastric Cancer

Seoul National University Hospital

Not applicable

308

Busan, Daegu, Daejeon, Goyang, Seongnam, Seoul, Suwon

2025-06-13

Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative

DrugsSPY001·SPY002·SPY003

Spyre Therapeutics, Inc.

Phase 2

645

Busan, Daegu, Daejeon, Seoul, Suwon, Wŏnju

2025-05-27

Recruiting

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800Primary Membranous Nephropathy

DrugsFelzartamab·Tacrolimus

Biogen

Phase 3

180

Suwon, Seoul, Busan

2025-05-22

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Goyang-si, Seongnam-si, Suwon, Hwasungun, Cheongju-si, Seocho-gu, Daegu, Incheon

2025-05-22

Recruiting

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

NCT06711887Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

348

Suwon, Seoul

2025-05-19

Active, closed

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

NCT06806852Head and Neck Squamous Cell Carcinoma

DrugsBI 770371·Cetuximab·Pembrolizumab

Boehringer Ingelheim

Phase 1

Seoul, Suwon

2025-05-14

Active, closed

Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization

NCT06767345Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic

Korea University Anam Hospital

Phase 4

408

Seoul, Goyang, Suwon

2025-05-12

Recruiting

ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74

NCT06714513Tuberculosis, Pulmonary

Quratis Inc.

Phase 1

144

Gwangmyeong, Seoul, Suwon

2025-05-09

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357Immunoglobulin A Nephropathy (IgAN)

DrugFelzartamab

Biogen

Phase 3

454

Busan, Anyang-si, Seongnam-si, Suwon, Seoul

2025-05-08

Recruiting

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

NCT06952699Narcolepsy Type 2

DrugTAK-360

Takeda

Phase 2

Junggu, Suwon, Seoul

2025-05-06

Recruiting

Post Marketing Study on Pluvicto in Korea

NCT06514521Metastatic Castration-resistant Prostate Cancer

Novartis Pharmaceuticals

Observational

278

Seongnam-si, Suwon, Busan, Gyeonggi-do, Seoul, Jeollanam

2025-04-18

Recruiting

Imjudo & Imfinzi PMS

NCT06544629Hepatocellular Carcinoma

AstraZeneca

Observational

246

Busan, Goyang, Seongnam, Seoul, Suwon

2025-04-14

Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan

Gilead Sciences

Phase 3

695

Changwon-Si, Gwangju, Seongbuk-Gu, Seongnam, Seoul, Suwon, Ulsan

2025-04-04

Recruiting

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

NCT06902545Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugZolbetuximab

Astellas Pharma Korea, Inc.

Observational

377

Goyang-si, Suwon, Yangsan, Hwasun Gun, Daejeon, Seoul

2025-04-03

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Goyang-si, Seoul, Suwon

2025-03-27

By invitation

Evaluation of the Impact of Dietary Education and Intervention on Gout Patients Receiving Urate-Lowering Therapy

NCT07834840Gout Disease, Gout

Sung Keon Cho

Not applicable

300

Suwon

2025-03-26

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Bucheon-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon, Wŏnju, Yangsan

2025-03-14

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Suwon, Seoul

2025-03-03

Not yet open

Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry

NCT06843421Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular Diseases

Korea University

Observational

6,000

Gyeonggi-do, Yongin, Seoul, Gangwon-do, Suwon

2025-03-01

Recruiting

South Korean Study to Prevent Frailty and Aging-related Diseases Through Lifestyle Intervention

NCT06891573Frailty

Seong Hye Choi, MD

Not applicable

Incheon, Seoul, Suwon

2025-02-26

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Cheongju-si, Seongnam, Suwon, Seoul, Daegu

2025-02-25

Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355Extensive-stage Small-cell Lung Cancer

DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin

BioNTech SE

Phase 3

621

Seoul, Goyang-si, Suwon, Jinju, Incheon, Cheongju-si

2025-02-03

Recruiting

SB17170 Phase 2 Trial in IPF Patients

NCT06747923IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

DrugSB17170

SPARK Biopharma

Phase 2

Goyang, Gwangmyeong, Seoul, Suwon

2025-01-27

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Anyang-si, Suwon, Gwangju, Seoul

2025-01-15

Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer

DrugZanidatamab

Jazz Pharmaceuticals

Phase 2

200

Suwon, Hwasun-Eup, Gangnam-gu, Guro-gu, Jongno-gu, Seodaemun-gu, Seoul

2025-01-14

Recruiting

IRIS-Coroflex NEO Cohort

NCT06177743Coronary Artery Stenosis, Coronary Artery Disease

Seung-Jung Park

Observational

1,000

Seoul, Bucheon-si, Daegu, Gwangju, Ilsan, Sejong, Suwon, Uijeongbu-si

2025-01-09

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon

2025-01-07

Recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910Crohn's Disease

DrugsVedolizumab·Upadacitinib

Takeda

Phase 3

396

Busan, Daegu, Daejeon, Seoul, Suwon

2025-01-02

Active, closed

Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

NCT06926933CPP

DrugEligard

HanAll BioPharma Co., Ltd.

Phase 4

Ansan, Jeonju, Kwangju, Seongnam, Seoul, Suwon

2024-12-12

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Daegu, Seoul, Suwon

2024-12-11

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140COVID-19 SARS-CoV-2 Infection

DrugIbuzatrelvir

Pfizer

Phase 3

2,330

Namdong-gu, Tonggu, Wŏnju, Gwangju, Ansan-si, Suwon, Dongjak-gu, Gangnam-gu

2024-12-08

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Gwangju, Seongnam-si, Seoul, Suwon

2024-12-04

Active, closed

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

Daegu, Seoul, Suwon

2024-12-01

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Suwon, Cheongju-si, Daegu, Goyang-si, Seoul

2024-11-25

Active, closed

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

NCT06567769Sanfilippo Syndrome Type A

GC Biopharma Corp

Phase 1

Suwon, Seoul

2024-11-21

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

Busan, Incheon, Seoul, Suwon

2024-11-21

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Busan, Daegu, Hwasun-gun, Incheon, Jeonju, Seongnam-si, Seoul, Suwon

2024-11-19

Recruiting

Prediction of Atrial Fibrillation Using Polygenic Risk Score

NCT07641582Atrial Fibrillation (AF)

Seoul St. Mary's Hospital

Not applicable

800

Incheon, Seoul, Suwon, Uijeongbu-si

2024-11-19

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Changwon-si, Cheongju-si, Incheon, JinJoo, Seoul, Suwon

2024-11-18

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Goyang-si, Suwon, Seoul

2024-10-21

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

Busan, Chungcheongbuk-do, Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon

2024-10-04

Recruiting

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

NCT06616766NSCLC (Non-small Cell Lung Cancer), Solid Tumor

Yuhan Corporation

Phase 1/2

201

Seongnam-si, Suwon, Cheongju-si, Seoul

2024-10-02

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Busan, Goyang-si, Hwasun, Seoul, Suwon

2024-09-25

Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor

DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin

Eli Lilly and Company

Phase 1

340

Ilsandong-gu, Seoul, Suwon

2024-09-19

Active, closed

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

DrugsABP 234·Pembrolizumab

Amgen

Phase 3

163

Suwon, Jeonju, Cheongju-si, Busan, Incheon, Seoul

2024-09-12

Active, closed

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

DrugsABP 234·Keytruda·Pembrolizumab

Amgen

Phase 3

315

Suwon, Jeonju, Cheongju-si, Seoul

2024-09-09

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

555

Suwon, Jinju, Yangsan, Hwasun-gun, Chungcheongbuk-do, Jongno -Gu, Seoul

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

Seongnam, Seoul, Suwon

2024-08-27

Recruiting

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

NCT06184009Pediatric Acute Lymphoblastic Leukemia

Jae Wook Lee

Phase 2

370

Seoul, Incheon, Suwon, Yangsan

2024-08-10

Active, closed

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer

DrugsPumitamig·Topotecan·Etoposide·Paclitaxel

BioNTech SE

Phase 2

110

Cheongju-si, Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon

2024-08-05

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

3,000

Wŏnju, Gwangju, Seongnam, Suwon, Cheongju-si, Busan, Haeundae-gu, Daegu

2024-08-05

Recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Rituximab

AstraZeneca

Phase 2

Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon

2024-07-16

Active, closed

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441Resectable Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Taxol

Regeneron Pharmaceuticals

Phase 2

195

Gyeonggi-do, Suwon, Hwasun, Incheon, Seoul, Ulsan

2024-07-16

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

963

Seongdong, Ansan, Seongnam-si, Seoul, Suwon

2024-07-11

Recruiting

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy

Walden Biosciences

Phase 2

Anyang, Busan, Seongnam-si, Seoul, Soeul, Suwon

2024-07-02

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Bucheon-si, Goyang-si, Seongnam-si, Suwon, Yangsan, Busan, Cheongju-si, Daegu

2024-06-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Busan, Goyang-si, Hwasun, Seoul, Soeul, Suwon

2024-06-25

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

Goyang-si, Seongnam, Suwon, Busan, Seoul, Deagu

2024-06-19

Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

NCT06500273Large B-cell Lymphoma

DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide

Allogene Therapeutics

Phase 2

250

Seogu, Goyang-si, Suwon, Hwasun, Seoul

2024-06-18

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

200

Ansan-si, Bucheon-si, Suwon, Seoul

2024-06-14

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754Non-small Cell Lung Cancer (NSCLC)

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

550

Goyang-si, Seongnam, Suwon, Pusan, Cheongju-si, Busan, Daegu, Junggu

2024-06-11

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

Busan, Suwon, Yangsan, Jeonju, Seoul

2024-06-07

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Wŏnju, Ansan-si, Suwon, Busan, Haeundae-gu, Dongjak-gu, Daegu, Daejeon

2024-06-05

Active, closed

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification

DrugsELVN-002·Eribulin·Leucovorin·Trastuzumab

Enliven Therapeutics

Phase 1

275

Seongnam-si, Seoul, Soeul, Suwon

2024-05-30

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Bupyeong-gu, Hwasun, Suwon, Yangsan, Daegu, Junggu, Incheon, Seoul

2024-05-24

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon

2024-05-21

Active, closed

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms

DrugsTucatinib·Disitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

Seongnam-si, Busan, Goyang-si, Seoul, Cheongju-si, Incheon, Suwon

2024-05-20

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Daegu, Gwangju, Ansan-si, Seongnam-si, Suwon, Yangsan, Bupyeong-gu, Seoul

2024-05-08

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

Goyang-si, Namdong-gu, Seoul, Suwon

2024-04-29

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Busan, Gyeonggi-do, Pusan, Seongnam-si, Seoul, Suwon

2024-04-29

Active, closed

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

Cheongju-si, Seongnam-si, Seoul, Suwon

2024-04-21

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Changwon, Incheon, Seongnam-si, Seoul, Suwon

2024-04-11

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul

2024-04-03

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Anyang-si, Busan, Deagu, Gwangju, Gyeonggi-do, Seoul, Suwon

2024-03-29

Recruiting

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

NCT07699328EGFR-Mutant Non-Small Cell Lung Cancer

Voronoi, Inc

Phase 1/2

315

Seongnam-si, Suwon, Cheongju-si, Seoul

2024-03-26

Recruiting

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

NCT06099366Lymphoblastic Leukemia in Children

Hee Young Ju

Phase 2

116

Seoul, Yangsan, Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Suwon

2024-03-05

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Suwon

2024-02-21

Active, closed

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

NCT06230224B-Cell Non-Hodgkin Lymphoma (B-NHL)

DrugsOdronextamab·Ifosfamide·Paraplatin·Cytarabine

Regeneron Pharmaceuticals

Phase 3

216

Gyeonggi-do, Suwon, Yangsan, Jeonju, Incheon, Busan, Daegu, Seoul

2024-02-15

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Cheongiu, Goyang, Incheon, Seoul, Suwon

2024-02-09

Recruiting

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

NCT05910827Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma

DrugsHMBD-001·Cetuximab·Docetaxel

Hummingbird Bioscience

Phase 1/2

398

Cheongju-si, Seongnam-si, Seoul, Suwon

2024-02-05

Recruiting

Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

NCT06186037Coronary Artery Disease, Dyslipidemias, Primary Prevention

Saint Vincent's Hospital, Korea

Phase 4

6,356

Suwon

2024-02-01

Active, closed

Individualized Versus Conventional Perioperative Blood Pressure Management

NCT06225453Major Non-cardiac Surgery

Seoul National University Hospital

Not applicable

1,896

Seongnam, Seoul, Suwon

2024-01-29

Recruiting

A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients

NCT06249919Seneorineural Deafness, Sudden Sensorineural Hearing Loss

Neuracle Science Co., LTD.

Phase 1/2

138

Bucheon-si, Gwangju, Ilsan, Pusan, Pyeongchon, Seongnam, Seoul, Suwon

2024-01-19

Active, closed

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

NCT06163326Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

394

Suwon, Seoul

2024-01-19

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Busan, Wŏnju, Seongnam-si, Seoul, Suwon, Incheon, Cheonan, Ulsan

2024-01-18

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Daegu, Seoul, Suwon

2024-01-11

Active, closed

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

NCT06256328Gastric Cancer

DrugsONO-4578·Teysuno·Opdivo·Nivolumab

Ono Pharmaceutical Co., Ltd.

Phase 2

226

Busan, Anyang-si, Goyang-si, Seongnam-si, Suwon, Yangsan, Jeonju, Hwasun-gun

2024-01-10

Active, closed

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632Advanced or Metastatic Breast Cancer

DrugsExemestane·Everolimus·Fulvestrant

Pfizer

Phase 2

333

Suwon, Seoul

2024-01-09

Active, closed

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

124

Seoul, Suwon

2024-01-03

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Suwon, Jeonju, Incheon, Busan, Daegu, Seoul, Ulsan

2023-12-28

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Cheongju-si, Daegu, Deagu, Gangnam-gu, Goyang-si, Hwasun, Seoul, Suwon

2023-12-21

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Daejeon, Bucheon-si, Suwon, Seoul

2023-12-19

Active, closed

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

285

Seongnam-si, Suwon, Jinju, Incheon, Seoul

2023-12-18

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Wŏnju, Goyang-si, Suwon, Cheongju-si, Daegu, Seoul

2023-12-15

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Goyang-si, Gyeonggi-do, Incheon, Seoul, Suwon

2023-12-14

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

904

Suwon, Incheon, Busan, Daegu, Seoul

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Goyang-si, Suwon, Jeonju, Busan, Daegu, Seoul

2023-12-12

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Suwon, Seoul

2023-12-07

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul

2023-12-06

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Daejeon, Seongnam-si, Seoul, Suwon

2023-11-21

Active, closed

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Exemestane·Anastrozole·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

510

Suwon, Busan, Seoul

2023-11-16

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

289

Busan, Daejeon, Suwon, Seoul, Daegu

2023-11-15

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Hwasun, Goyang-si, Seongnam, Suwon, Yangsan, Cheongju-si, Busan, Junggu

2023-11-12

Recruiting

Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe)

NCT05971225Congestive Heart Failure, Defibrillators, Cardiac Resynchronization Therapy

Saint Vincent's Hospital, Korea

Not applicable

450

Suwon

2023-11-11

Recruiting

CeraFlex PFO Closure System PMCF Study

NCT06120270Patent Foramen Ovale

Lifetech Scientific (Shenzhen) Co., Ltd.

Observational

180

Gwangju, Daegu, Seoul, Suwon

2023-11-03

Active, closed

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555Melanoma

DrugsOpdivo·Nivolumab

Amgen

Phase 3

633

Busan, Suwon, Seoul

2023-11-02

Recruiting

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

NCT06011954Urothelial Cancer

DrugEnfortumab Vedotin

Astellas Pharma Korea, Inc.

Observational

202

Goyang-si, Suwon, Jeollanam-do, Jeonju, Busan, Daegu, Daejeon, Incheon

2023-11-01

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Wŏnju, Suwon, Busan, Haeundae-gu, Dongjak-gu, Daegu, Daejeon, Seoul

2023-10-25

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Cheongju-si, Incheon, Jinju, Seoul, Suwon

2023-10-24

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugEnlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

14,550

Seongnam, Suwon, Busan, Daegu, Seoul

2023-10-09

Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

NCT06072131Peripheral T Cell Lymphoma

DrugsBelinostat·Pralatrexate·CHOP·Prednisone

Acrotech Biopharma Inc.

Phase 3

504

Busan, Ulsan, Suwon, Jinju, Jeonju, Daegu, Sinchon-dong, Songpa-dong

2023-10-04

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Goyang-si, Seongnam-si, Suwon, Hwasun-gun, Iksan-si, Busan, Incheon, Seoul

2023-09-22

Recruiting

Comparison of PROVISIONal 1-stent Strategy with DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.

NCT06002932Coronary Artery Disease, Ischemic Heart Disease

Saint Vincent's Hospital, Korea

Not applicable

750

Suwon

2023-09-08

Recruiting

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

NCT06156527Lazertinib

DrugLazertinib

National Cancer Center, Korea

Phase 2

120

Suwon, Goyang-si, Seoul

2023-09-05

Recruiting

The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement

NCT06015711Opioid Use

Ajou University School of Medicine

Not applicable

Suwon

2023-08-30

Recruiting

Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

NCT06202027FGF23-related Hypophosphataemic Rickets and Osteomalacia

Kyowa Kirin Korea Co., Ltd.

Observational

100

Wŏnju, Suwon, Yangsan, Gwangju, Sejong, Busan, Seoul

2023-08-11

Active, closed

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

NCT05800015Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Pemetrexed

Regeneron Pharmaceuticals

Phase 2/3

160

Seongnam-si, Suwon, Incheon, Cheongju-si, Daejeon, Seoul, Ulsan

2023-08-08

Recruiting

Study on Water Vapor Thermal Therapy

NCT06656689Benign Prostatic Hyperplasia

Saint Vincent's Hospital, Korea

Observational

300

Suwon

2023-07-31

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

DrugZipalertinib

Taiho Oncology, Inc.

Phase 2

220

Goyang-si, Suwon, Jinju, Incheon, Hwasun-gun, Seoul, Soeul

2023-07-31

Recruiting

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

NCT05394831EGFR Mutant Advanced Non-small Cell Lung Cancer

J Ints Bio

Phase 1/2

150

Goyang-si, Cheongju-si, Seoul, Suwon

2023-07-30

Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

NCT05954312Advanced Solid Tumors

DrugsDocetaxel·Paclitaxel·Pembrolizumab

Vividion Therapeutics, Inc.

Phase 1

290

Goyang, Incheon, Seongnam, Seoul, Suwon

2023-07-28

Recruiting

Asciminib RMP Study

NCT05943522Chronic Myeloid Leukemia

Novartis Pharmaceuticals

Observational

600

Wŏnju, Anyang-si, Bucheon-si, Uijeongbu-si, Gyeonggi-do, Incheon, Seoul, Suwon

2023-07-19

Recruiting

Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis

NCT06066450Drug-eluting Stent, Coronary Artery Disease

Genoss Co., Ltd.

Observational

1,000

Suwon

2023-07-07

Active, closed

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05785767Advanced Non-Small Cell Lung Cancer

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2/3

149

Incheon, Suwon, Cheongju-si, Daejeon, Seoul, Ulsan

2023-06-30

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Cheongju-si, Daegu, Goyang-si, Seoul, Suwon

2023-06-28

Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

NCT05703516Non-Small-Cell Lung Carcinoma

Novartis Pharmaceuticals

Observational

Daegu, Suwon, Incheon, Seoul, Busan, Daejeon, Jeollanam

2023-06-12

Active, closed

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903Obesity, Overweight, Overweight or Obesity

DrugOrforglipron

Eli Lilly and Company

Phase 3

3,127

Namdong-gu, Ansan-si, Anyang-si, Suwon, Busan, Seoul, Seogu

2023-06-05

Recruiting

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

NCT05827523Ovarian Cancer

DrugCisplatin

National Cancer Center, Korea

Phase 3

520

Sejong, Goyang-si, Suwon, Pusan, Seoul

2023-05-31

Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)

DrugsEribulin·Trastuzumab deruxtecan·Doxorubicin·Keytruda

GI Innovation, Inc.

Phase 1/2

358

Seoul, Suwon

2023-05-30

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Suwon, Seoul, Gwangju

2023-05-20

Active, closed

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

NCT05816252Non-small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab

Klus Pharma Inc.

Phase 2

356

Suwon, Cheongju-si, Seoul, Busan

2023-04-19

Recruiting

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

NCT05686759Hepatitis B

GC Biopharma Corp

Phase 3

105

Goyang-si, Suwon, Seoul, Busan, Daejeon

2023-04-13

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Suwon, Incheon, Seoul

2023-03-20

Active, closed

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

DrugPovetacicept

Alpine Immune Sciences, Inc.

Phase 1/2

Cheonan, Anyang-si, Goyang-si, Guri-si, Seoul, Suwon

2023-03-15

Recruiting

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer

DrugsTU2218·Keytruda·Pembrolizumab

TiumBio Co., Ltd.

Phase 1/2

140

Seongnam, Seoul, Suwon

2023-03-10

Recruiting

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

NCT05744921Paroxysmal Nocturnal Hemoglobinuria

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

202

Suwon, Incheon, Busan, Seoul

2023-03-07

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

Namdong-gu, Goyang-si, Seongnam, Suwon, Seoul

2023-03-03

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

Fore Biotherapeutics

Phase 2

254

Suwon, Pusan, Hwasun, Seoul

2023-02-21

Active, closed

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack

DrugDexpramipexole Dihydrochloride

Areteia Therapeutics

Phase 3

600

Anyang-si, Bucheon-si, Busan, Gwangju, Incheon, Jeonju, Seoul, Suwon

2023-01-30

Recruiting

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

NCT05541822Advanced Solid Tumors

DrugLazertinib

Abion Inc

Phase 2

178

Goyang-si, Suwon, Dongjak, Seoul, Sinchon-dong, Cheongju-si, Incheon, Jinju

2023-01-17

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Wŏnju, Seongnam-si, Suwon, Daegu, Ansan-si, Busan, Daejeon, Incheon

2023-01-16

Active, closed

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT05617677Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

516

Gwangju, Suwon, Seoul

2023-01-12

Active, closed

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

NCT05662241IgG4 Related Disease

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 3

194

Seoul, Suwon

2023-01-09

Active, closed

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266NSCLC

DrugsDato-DXd·Durvalumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 3

1,350

Busan, Cheongju-si, Jinju, Seoul, Suwon

2022-12-29

Recruiting

Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

NCT05534087Colon Cancer

DrugFolfox

Seoul National University Hospital

Phase 3

236

Busan, Daegu, Goyang, Hwasun, Seongnam, Seoul, Suwon

2022-12-15

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Daegu, Hwaseong-si, Suwon, Incheon, Seoul, Gwangju

2022-12-09

Active, closed

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

NCT05389449Paroxysmal Nocturnal Hemoglobinuria

DrugDanicopan

Alexion Pharmaceuticals, Inc.

Phase 3

Seoul, Suwon

2022-10-28

Active, closed

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237Non-small Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed

Gilead Sciences

Phase 3

1,021

Gangnam-Gu, Goyang, Heungdeok-Gu, Inchon, Seoul, Suwon

2022-10-12

Active, closed

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor

DrugElironrasib

Revolution Medicines, Inc.

Phase 1

222

Suwon, Seoul

2022-09-19

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Busan, Daegu, Gwangju, Gyeonggi-do, Hwaseong-si, Seoul, Suwon, Wŏnju

2022-09-19

Active, closed

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327Systemic Lupus Erythematosus

DrugEnpatoran

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2

379

Incheon, Seoul, Suwon

2022-09-16

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

Cheongju-si, Seoul, Suwon

2022-09-15

Active, closed

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510Colitis, Ulcerative

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

418

Busan, Daegu, Goyang-si, Gwangju, Gyeonggi-do, Seoul, Suwon

2022-09-13

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Ansan-si, Suwon, Daejeon, Gwangju, Seoul

2022-09-13

Recruiting

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

NCT05523947HER2-Positive Solid Tumor

Yuhan Corporation

Phase 1/2

147

Seongnam-si, Suwon, Jinju, Cheongju-si, Incheon, Seoul, Ulsan

2022-08-26

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Daegu, Gwangju, Ansan-si, Seongnam-si, Suwon, Yangsan, Bupyeong-Gu, Seoul

2022-08-22

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon

2022-08-03

Active, closed

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

NCT05133531Paroxysmal Nocturnal Hemoglobinuria

DrugsSoliris·Ultomiris·Cemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

202

Suwon, Incheon, Busan, Seoul

2022-08-01

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Busan, Daegu, Goyang-si, Gwangju, Hwaseong-si, Seongnam-si, Seoul, Suwon

2022-07-22

Active, closed

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555Diffuse Large B Cell Lymphoma

DrugsTafasitamab·Lenalidomide

Incyte Corporation

Phase 1/2

Suwon, Busan, Daegu, Incheon, Jeonju, Seoul, Ulsan

2022-07-19

Active, closed

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

452

Bundang Gu, Suwon, Gwangju, Seoul

2022-07-14

Active, closed

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634Myositis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2

Seoul, Suwon

2022-07-05

Recruiting

A Post Marketing Surveillance on Piqray in Korea

NCT05293470Breast Cancer

Novartis Pharmaceuticals

Observational

900

Cheonan Si, Daegu, Goyang-si, Suwon, Gyeonggi-do, Seoul, Busan, Daejeon

2022-06-29

Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

NCT05405595Advanced/Metastatic Solid Tumors

DrugsADG126·Keytruda·Pembrolizumab

Adagene Inc

Phase 1/2

186

Seogu, Seongnam, Suwon, Cheongju-si, Seoul, Daegu

2022-06-15

Active, closed

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766Gastrointestinal Tract Malignancies

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Fluorouracil

Arcus Biosciences, Inc.

Phase 2

332

Busan, Daegu, Hwasun, Seongnam-si, Seoul, Suwon

2022-06-10

By invitation

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919Systemic Lupus Erythematosus (SLE)

DrugLitifilimab

Biogen

Phase 3

864

Suwon, Seoul

2022-06-10

Active, closed

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974Non-small Cell Lung Cancer

DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin

Gilead Sciences

Phase 2

193

Cheongju-si, Inchon, Seoul, Suwon

2022-05-30

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

Busan, Chungcheongbuk-do, Seongnam-si, Seoul, Suwon

2022-04-14

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

Goyang-si, Seongnam, Suwon, Jinju, Yangsan, Cheongju-si, Seoul

2022-03-25

Active, closed

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582HER2 Positive Breast Cancer

DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

654

Wŏnju, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Seoul, Busan, Incheon

2022-03-07

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Daegu, Jinju, Seoul, Suwon

2022-02-21

Recruiting

Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement

NCT04258488AORTIC VALVE DISEASES, Thromboembolism

DrugsWarfarin·Rivaroxaban

Joon Bum Kim

Phase 4

1,300

Bucheon-si, Busan, Daegu, Gangneung, Gwangju, Seongnam, Seoul, Suwon

2022-02-21

Active, closed

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895Non-Small Cell Lung Cancer

DrugsDomvanalimab·Durvalumab

AstraZeneca

Phase 3

791

Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon

2022-02-18

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Changwon-si, Cheongju-si, Seongnam-si, Seoul, Suwon

2022-02-07

Active, closed

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634Partial Epilepsy

SK Life Science, Inc.

Phase 3

140

Cheonju, Seoul, Suwon

2022-01-10

Recruiting

RibFix Blu Thoracic Fixation System Versus Non-surgical Treatment in Non-flail Chest Rib Fractures

NCT05146986Rib; Fracture

Zimmer Biomet

Observational

167

Wŏnju, Suwon

2022-01-02

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Seoul, Suwon

2021-12-10

Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

NCT05103683Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC

DrugTORL-1-23

TORL Biotherapeutics, LLC

Phase 1

Suwon, Seoul

2021-11-17

Active, closed

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

NCT05144854Gastric Cancer

DrugsTeysuno·Yervoy·Ipilimumab·Opdivo

Ono Pharmaceutical Co., Ltd.

Phase 3

626

Busan, Anyang-si, Goyang-si, Seongnam-si, Suwon, Daegu, Yangsan, Jeonju

2021-11-05

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

400

Seongnam-si, Suwon, Chungcheongbuk-do, Jongno -Gu, Seoul

2021-10-25

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Cheonan-si, Namdong-gu, Suwon, Daegu, Busan, Seoul

2021-10-04

Recruiting

Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI

NCT04812431Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion, Spinal Cord Injury at C5-C7 Level With Complete Lesion

S.Biomedics Co., Ltd.

Phase 1/2

Suwon, Seoul

2021-09-23

Recruiting

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer

DrugsKeytruda·Pembrolizumab

Medicenna Therapeutics, Inc.

Phase 1/2

115

Seoul, Seongnam-si, Suwon

2021-08-27

Recruiting

Regulatory Post-Marketing Surveillance Study for Brolucizumab

NCT04985487Neovascular Age-related Macular Degeneration

Novartis Pharmaceuticals

Observational

3,000

Daegu, Goyang-si, Guri-si, Suwon, Iksan Si, Daejeon, Busan, Gwangju

2021-08-18

Recruiting

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

NCT04977453Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma

DrugsLenvatinib·Keytruda·Pembrolizumab

GI Innovation, Inc.

Phase 1/2

317

Seoul, Daejeon, Suwon

2021-08-02

Active, closed

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed

Eli Lilly and Company

Phase 1/2

540

Goyang-si, Suwon, Hwasun-gun, Seoul

2021-07-19

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

Anyang-si, Busan, Daejeon, Goyang-si, Hwasun-gun, Seongnam-si, Seoul, Suwon

2021-06-24

Active, closed

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

NCT04651634Head and Neck Squamous Cell Carcinoma, Oral Mucositis

DrugCCRT

MitoImmune Therapeutics

Phase 2

Suwon, Jeonju, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seoul

2021-06-21

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

Cheonan-si, Gwangju, Seoul, Suwon

2021-06-17

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

548

Suwon, Busan, Incheon, Seoul

2021-05-25

Active, closed

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

NCT04675294Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

DrugsEvorpacept·Keytruda·Pembrolizumab

ALX Oncology Inc.

Phase 2

189

Cheongju-si, Daegu, Daejeon, Gyeonggi-do, Incheon, Seongnam, Seoul, Suwon

2021-04-02

Active, closed

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer

DrugsDomvanalimab·Zimberelimab·Pemetrexed·Paclitaxel

Arcus Biosciences, Inc.

Phase 2

169

Daegu, Incheon, Jinju, Seoul, Suwon

2021-02-08

Active, closed

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

DrugPembrolizumab

BioNTech SE

Phase 2/3

358

Hwasun, Seoul, Suwon

2021-01-07

Active, closed

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204Small Cell Lung Cancer

DrugsOlaparib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

672

Goyang-si, Seongnam-si, Suwon, Busan, Songpagu, Daegu, Seoul

2020-12-08

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsAdagrasib·Pembrolizumab

Mirati Therapeutics Inc.

Phase 2/3

626

Busan, Cheongju-si, Daegu, Goyang-si, Junggu, Seoul, Suwon

2020-12-02

Active, closed

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

NCT04639986Metastatic Breast Cancer

DrugsCapecitabine Product·Eribulin·Vinorelbine·Xeloda

Gilead Sciences

Phase 3

331

Busan, Seongnam, Seoul, Suwon

2020-11-23

Active, closed

Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

NCT03426904Colon Cancer

Kyungpook National University Hospital

Phase 3

708

Hwasun, Daegu, Seoul, Suwon

2020-10-23

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Daegu, Seoul, Suwon

2020-10-19

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Busan, Goyang-si, Jeonju, Seoul, Suwon

2020-10-08

Recruiting

Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

NCT04499859Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity

DrugsEzetimibe·Rosuvastatin

Kiyuk Chang, MD,PhD

Phase 4

3,548

Bucheon-si, Suwon, Uijeongbu-si, Daejeon, Incheon, Seoul

2020-10-01

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844Prostatic Neoplasms

DrugsAbiraterone acetate·Prednisone

Janssen Research & Development, LLC

Phase 3

696

Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Seongnam-si, Seoul, Suwon

2020-09-23

Active, closed

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283Diffuse Large B-cell Lymphoma

DrugsBrentuximab Vedotin·Lenalidomide·Rituximab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

239

Goyang-si, Suwon, Jeonju, Busan, Daegu, Incheon, Seoul

2020-08-20

Active, closed

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsParaplatin·Taxol·Olaparib·Etoposide

Merck Sharp & Dohme LLC

Phase 3

870

Goyang-si, Seongnam-si, Suwon, Jinju, Cheongju-si, Daegu, Seoul

2020-07-06

Recruiting

Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION)

NCT04370496Cervical Cancer, Cervical Cancer Stage IB1, Minimally Invasive Surgery

Seoul National University Hospital

Not applicable

124

Seoul, Suwon

2020-07-02

Active, closed

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

996

Wŏnju, Ansan-si, Guri-si, Suwon, Gyeongsan-si, Busan, Haeundae-gu, Dongjak-gu

2020-06-22

Active, closed

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

DrugTazemetostat

Epizyme, Inc.

Phase 3

599

Seoul, Busan, Incheon, Suwon

2020-06-11

Active, closed

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

NCT04269200Endometrial Neoplasms

DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

805

Goyang-si, Seoul, Suwon, Yangsan

2020-05-05

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

Busan, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul, Suwon

2020-04-16

Active, closed

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099NSCLC

Regeneron Pharmaceuticals

Phase 1/2

Gyeonggi-do, Seongnam-si, Suwon, Pusan, Hwasun, Incheon, Cheongju-si, Busan

2020-01-07

Active, closed

Role of FFR in ACS Patients: Pressure ACS Registry

NCT05896501Acute Coronary Syndrome

The Catholic University of Korea

Observational

500

Suwon, Uijeongbu-si, Daejeon, Incheon, Seoul

2020-01-01

Active, closed

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation

DrugZipalertinib

Cullinan Therapeutics Inc.

Phase 1/2

284

Goyang-si, Gyeonggi-do, Incheon, Seoul, Soeul, Suwon

2019-10-31

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Busan, Daegu, Gyeonggi-do, Incheon, Seongnam-si, Seoul, Suwon

2019-09-26

Active, closed

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 3

896

Wŏnju, Suwon, Busan, Daegu

2019-09-05

Active, closed

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

NCT03687359Dermatitis Atopic

Sanofi

Observational

1,860

Ansan-si, Suwon, Incheon, Seoul

2019-08-15

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

Seongnam-si, Seoul, Gyeonggi-do, Suwon

2019-08-09

Active, closed

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

NCT03974022Non-Small Cell Lung Cancer

DrugSunvozertinib

Dizal Pharmaceuticals

Phase 1/2

315

Cheonju, Goyang, Seongnam, Seoul, Suwon

2019-07-09

Active, closed

A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study

NCT05955235Pancreatitis, Acute

SCM Lifescience Co., LTD.

Observational

Bucheon-si, Daegu, Goyang-si, Gwangju, Incheon, Suwon

2019-05-10

Active, closed

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine

Astellas Pharma Global Development, Inc.

Phase 2

393

Seongnam-si, Suwon, Daegu, Gyeonggi-do, Seoul

2019-03-15

Active, closed

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501Gastrointestinal Stromal Tumors

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

453

Seoul, Suwon

2019-02-08

Active, closed

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT03778229Carcinoma

DrugsSavolitinib·Osimertinib

AstraZeneca

Phase 2

367

Goyang-si, Seongnam-si, Seoul, Suwon

2019-01-09

Active, closed

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

NCT03737643Advanced Ovarian Cancer

DrugsOlaparib·Durvalumab·Paclitaxel·Bevacizumab

AstraZeneca

Phase 3

1,407

Goyang-si, Seongnam-si, Seoul, Suwon

2019-01-04

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Hwasun Gun, Goyang-si, Seongnam-si, Suwon, Seoul

2018-12-17

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Seoul, Wŏnju, Bundang Gu, Suwon, Gyeonggi-do, Cheongju-si, Incheon, Seongnam Gyeonggi

2018-12-07

Active, closed

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134Non-Small Cell Lung Cancer

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

825

Busan, Cheongju-si, Seongnam-si, Seoul, Suwon

2018-12-06

Active, closed

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

NCT03562637Triple Negative Breast Cancer

OBI Pharma, Inc

Phase 3

575

Busan, Goyang-si, Incheon, Seongnam-si, Seoul, Suwon

2018-12-05

Active, closed

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536Non-small Cell Lung Cancer

DrugTelisotuzumab vedotin

AbbVie

Phase 2

270

Goyang-si, Seongnam, Suwon, Yangsan, Incheon, Hwasun-gun, Cheongju-si, Seoul

2018-10-10

Active, closed

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

DrugsPonatinib·Imatinib·Cytarabine·Vincristine

Takeda

Phase 3

245

Suwon, Daegu, Jeonju, Busan

2018-10-04

Active, closed

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297Small Cell Lung Cancer

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

730

Changwon-si, Cheongju-si, Daegu, Goyang-si, Jinju, Seongnam-si, Seoul, Suwon

2018-09-27

Active, closed

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,246

Goyang-si, Incheon, Seoul, Suwon

2018-09-27

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Busan, Daejeon, Guri-si, Seongnam, Suwon, Seoul, Daegu

2018-08-28

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Inceon, Hwasun, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Gangnam-gu, Songpagu

2018-08-21

Active, closed

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973Metastatic Urothelial Cancer

DrugsDomvanalimab·Zimberelimab·Avelumab·Enfortumab Vedotin

Gilead Sciences

Phase 2

502

Daegu, Goyang-si, Gwangju, Hwasun, Seongbuk-Gu, Seoul, Suwon, Wŏnju

2018-08-13

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

565

Seongnam-si, Suwon, Seoul, Incheon

2018-06-21

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

NCT03755791Hepatocellular Carcinoma

DrugsSorafenib·Cabozantinib·Tecentriq·Atezolizumab

Exelixis

Phase 3

837

Goyang-si, Suwon, Busan, Incheon, Seoul

2018-06-10

Active, closed

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed

DrugsRucaparib·Opdivo·Nivolumab

pharmaand GmbH

Phase 3

1,097

Goyang-si, Seongnam-si, Incheon, Cheonan, Seoul, Suwon

2018-05-14

Active, closed

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

NCT03383458Hepatocellular Carcinoma, Liver Cancer

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

545

Suwon, Seoul, Daegu, Goyang-si, Gyeongsangnam-do, Jeollanam-do, Seongnam-si

2018-04-18

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Busan, Daegu, Daejeon, Guri-si, Seongnam-si, Suwon, Seoul

2018-04-09

Active, closed

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

NCT03315364Recurrent or Metastatic Breast Cancer

DrugsLiporaxel·Taxol·Paclitaxel

Daehwa Pharmaceutical Co., Ltd.

Phase 2/3

549

Wŏnju, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Busan, Daegu, Daejeon

2017-12-18

Active, closed

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

146

Goyang-si, Suwon, Busan, Seoul

2017-06-26

Active, closed

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608Carcinoma, Non-Small-Cell Lung

DrugsCrizotinib·Lorlatinib

Pfizer

Phase 3

296

Suwon, Seoul, Ulsan

2017-04-27

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068Ulcerative Colitis (UC)

DrugUpadacitinib

AbbVie

Phase 3

950

Busan, Guri-si, Seongnam, Suwon, Seoul, Daegu

2017-01-31

Active, closed

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

NCT03003962Non Small Cell Lung Carcinoma NSCLC

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

669

Changwon-si, Cheongju-si, Daegu, Incheon, Jinju, Seoul, Suwon

2017-01-02

Recruiting

Neurovascular Product Surveillance Registry

NCT02988128Intracranial Aneurysm, Stroke, Ischemic

Medtronic Neurovascular Clinical Affairs

Observational

4,000

Daejeon, Gwangju, Jeonju, Seoul, Suwon, Ulsan

2016-12

Active, closed

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV

DrugTepotinib

EMD Serono Research & Development Institute, Inc.

Phase 2

337

Busan, Daegu, Goyang-si, Hwasun-gun, Incheon, Seongnam-si, Seoul, Suwon

2016-09-13

Active, closed

Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)

NCT02859038Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

Shanghai Gynecologic Oncology Group

Phase 3

489

Seoul, Suwon

2016-08

Active, closed

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

NCT02531516Prostatic Neoplasms

DrugsGnRH·Bicalutamide·Apalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,503

Buk Gu, Gyeonggi-do, Jeollanam-do, Seoul, Suwon

2015-11-19

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

Cheongju-si, Seoul, Suwon

2015-10-21

Active, closed

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448Metastatic Non-Small Cell Lung Cancer

DrugsGefitinib·Erlotinib·Ramucirumab·Osimertinib

Eli Lilly and Company

Phase 3

545

Cheongju-si, Seongnam, Suwon, Jinju, Seoul, Ulsan

2015-05-06

Active, closed

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

NCT02152631Non Small Cell Lung Cancer

DrugsErlotinib·Abemaciclib

Eli Lilly and Company

Phase 3

453

Goyang-si, Incheon, Seoul, Seowon-Gu, Suwon, Ulsan

2014-10-03

Recruiting

The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer

NCT02920554Gallbladder Cancer

Saint Vincent's Hospital, Korea

Not applicable

Suwon

2014-07

Active, closed

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

NCT02099058Advanced Solid Tumors Cancer

DrugsTelisotuzumab vedotin·Erlotinib·Osimertinib·Nivolumab

AbbVie

Phase 1

237

Suwon, Seoul

2014-01-15

Active, closed

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00565851Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma

DrugsHD204·Bevacizumab-awwb·BP102·Zirabev

National Cancer Institute (NCI)

Phase 3

1,052

Dalseo-gu, Goyang-si, Seoul, Seongnam, Incheon, Suwon

2007-12-06

Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742Fabry Disease

Genzyme, a Sanofi Company

Observational

9,000

Suwon, Yangsan, Jeju City, Seoul, Busan, Daejeon

2001-07-31

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/suwon

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 334 of those studies with a site in Suwon.

How many clinical trials are recruiting in Suwon?

171 of the 334 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 152 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Suwon), 334 studies
Phase	Studies	Recruiting	Share
Phase 3	186	81	55.7%
Phase 2	50	27	15%
Observational	27	21	8.1%
Phase 1/2	21	15	6.3%
Not applicable	16	10	4.8%
Phase 2/3	13	5	3.9%
Phase 1	12	5	3.6%
Phase 4	9	7	2.7%

Most active sponsors

Lead sponsors with the most studies (Suwon)
Lead sponsor	Studies	Recruiting
AstraZeneca	37	17
Merck Sharp & Dohme LLC	19	10
Novartis Pharmaceuticals	13	9
AbbVie	12	4
Regeneron Pharmaceuticals	12	6
Eli Lilly and Company	11	5
Janssen Research & Development, LLC	11	3
Pfizer	9	4
Boehringer Ingelheim	6	4
Bristol-Myers Squibb	6	4

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.